SCHEMBL4273168

SCHEMBL4273168

CCOc1cc(-c2nc(CNC(=O)c3ncccc3C)co2)ccc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
GSK3B P49841 2/20 0.43
CDK2 P24941 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
S1PR1 P21453 3/20 0.41
S1PR3 Q99500 1/20 0.41
KLKB1 P03952 1/20 0.40
PKM P14618 2/20 0.40
HPGD P15428 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPT P10636 1/20 0.40
ADORA2A P29274 1/20 0.40
IDO1 P14902 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
MAPK1 P28482 1/20 0.39
CASP1 P29466 1/20 0.39
TLR9 Q9NR96 1/20 0.39
TLR8 Q9NR97 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4271695 0.94 GSK3B (0.45) LMNAGSK3BCDK2SMN1; SMN2PKM
SCHEMBL4275012 0.91 GSK3B (0.41) LMNAGSK3BCDK2KLKB1PKM
SCHEMBL4282848 0.90 GSK3B (0.41) LMNAGSK3BCDK2KLKB1PKM
SCHEMBL4276879 0.90 HSD17B10 (0.44) LMNAGSK3BCDK2SMN1; SMN2KLKB1
SCHEMBL4286005 0.90 S1PR1 (0.39) LMNAGSK3BCDK2S1PR1KLKB1
SCHEMBL4280816 0.90 GSK3B (0.41) GSK3BCDK2KLKB1PKMHPGD
SCHEMBL4278398 0.90 GSK3B (0.41) LMNAGSK3BCDK2SMN1; SMN2KLKB1
SCHEMBL4276096 0.90 GSK3B (0.42) LMNAGSK3BCDK2SMN1; SMN2S1PR1
SCHEMBL4270616 0.89 GSK3B (0.44) GSK3BCDK2KLKB1PKMHPGD
SCHEMBL4285870 0.89 PDE4A (0.43) GSK3BCDK2KLKB1PKMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICALC., LTD. (JP) 2026-04-23 US disclosed
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-05-09 US disclosed
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-08-25 US disclosed
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-03-12 US disclosed
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-03-07 US disclosed
US-RE46792-E1 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-04-17 US disclosed
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
EP-1954684-B1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2014-05-07 EP disclosed
US-20140100226-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-04-10 US disclosed
US-8637559-B2 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-28 US disclosed
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-09-03 US disclosed
EP-1954684-A2 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION Otsuka Pharmaceutical Co., Ltd. (JP) 2008-08-13 EP disclosed
WO-2007058338-A9 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2007-11-01 WO disclosed
WO-2007058338-A2 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LMNA 3948/4885GSK3B 646/4885CDK2 900/4885
US-20140100226-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LMNA 3948/4885GSK3B 646/4885CDK2 900/4885
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LMNA 3948/4885GSK3B 646/4885CDK2 900/4885
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE7B, PDE4B, PDE1B LMNA 3066/4885GSK3B 754/4885CDK2 3134/4885
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LMNA 3948/4885GSK3B 646/4885CDK2 900/4885
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LMNA 3948/4885GSK3B 646/4885CDK2 900/4885
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LMNA 3950/4885GSK3B 599/4885CDK2 914/4885
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LMNA 3948/4885GSK3B 646/4885CDK2 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.